Literature DB >> 21602155

[Human umbilical cord mesenchymal stem cells with adenovirus-mediated interleukin 12 gene transduction inhibits the growth of ovarian carcinoma cells both in vitro and in vivo].

Wen-hong Zhao1, Jian-xin Cheng, Peng-fei Shi, Jun-yan Huang.   

Abstract

OBJECTIVE: To study the inhibitory effect of human umbilical cord mesenchymal stem cells (UC-MSCs) infected by a adenoviral vector containing interleukin 12 (IL-12) gene on the proliferation of ovarian carcinoma SKOV3 in vitro and the growth of tumor explants in nude mice.
METHODS: Cultured human UC-MSCs were infected with the recombinant adenovirus vector harboring IL-12 gene to establish the IL-12-expressing cell line AdIL-12-MSCs. Western blotting and RT-PCR were used to detect IL-12 expressions in AdIL-12-MSCs at the protein and mRNA levels, respectively. ELISA were used to detect IL-12 content in the supernatant of AdIL-12-MSCs, whose effect on the proliferation and apoptosis of ovarian carcinoma SKOV3 cells was evaluated with MTT assay and flow cytometry, respectively. In a nude mouse model bearing subcutaneous SKOV3 tumor explants, AdIL-12-MSCs were infused via the tail vein and the inhibitory effect on the tumor growth was observed.
RESULTS: The exogenous IL-12 gene was successfully transduced into UC-MSCs by the recombinant adenovirus vector, resulting in efficient IL-12 expression in the cell at both the protein and mRNA levels. The supernatant of AdIL-12-MSCs significantly inhibited the proliferation of SKOV3 cells and induced cellular apoptosis in vitro as compared with UC-MSC supernatant. In the tumor-bearing nude mouse model, the transplantation of AdIL-12-MSCs significantly inhibited the growth of SKOV3 tumor explants (P<0.05).
CONCLUSION: Human UC-MSCs with IL-12 gene transduction, which express IL-12 at protein and mRNA levels, can inhibit the proliferation and induce apoptosis of ovarian carcinoma SKOV3 cells in vitro, and suppress the growth of ovarian cancer explants in nude mice.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21602155

Source DB:  PubMed          Journal:  Nan Fang Yi Ke Da Xue Xue Bao        ISSN: 1673-4254


  7 in total

Review 1.  Mesenchymal stem cells as delivery vectors for anti-tumor therapy.

Authors:  Zhenzhen Li; Dongmei Fan; Dongsheng Xiong
Journal:  Stem Cell Investig       Date:  2015-03-26

2.  Effect of human Wharton's jelly mesenchymal stem cell secretome on proliferation, apoptosis and drug resistance of lung cancer cells.

Authors:  F Hendijani; Sh Haghjooy Javanmard; L Rafiee; H Sadeghi-Aliabadi
Journal:  Res Pharm Sci       Date:  2015 Mar-Apr

Review 3.  Mesenchymal stem cells in acute myeloid leukemia: a focus on mechanisms involved and therapeutic concepts.

Authors:  Ezzatollah Fathi; Zohreh Sanaat; Raheleh Farahzadi
Journal:  Blood Res       Date:  2019-09-25

Review 4.  Mesenchymal stem cells in cancer therapy; the art of harnessing a foe to a friend.

Authors:  Mehdi Karimi-Shahri; Hossein Javid; Alireza Sharbaf Mashhad; Shaghayegh Yazdani; Seyed Isaac Hashemy
Journal:  Iran J Basic Med Sci       Date:  2021-10       Impact factor: 2.699

Review 5.  Application of Mesenchymal Stem Cells for Therapeutic Agent Delivery in Anti-tumor Treatment.

Authors:  Daria S Chulpanova; Kristina V Kitaeva; Leysan G Tazetdinova; Victoria James; Albert A Rizvanov; Valeriya V Solovyeva
Journal:  Front Pharmacol       Date:  2018-03-20       Impact factor: 5.810

Review 6.  Mesenchymal stem cells in suppression or progression of hematologic malignancy: current status and challenges.

Authors:  Myoung Woo Lee; Somi Ryu; Dae Seong Kim; Ji Won Lee; Ki Woong Sung; Hong Hoe Koo; Keon Hee Yoo
Journal:  Leukemia       Date:  2019-01-31       Impact factor: 11.528

7.  IL7-IL12 Engineered Mesenchymal Stem Cells (MSCs) Improve A CAR T Cell Attack Against Colorectal Cancer Cells.

Authors:  Andreas A Hombach; Ulf Geumann; Christine Günther; Felix G Hermann; Hinrich Abken
Journal:  Cells       Date:  2020-04-03       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.